Huang Guo, deputy director of the National Medical Products Administration (NMPA), recently led a team to Shandong Province, where they visited pharmaceuticals and research institutes to conduct in-depth research on promoting the high-quality development of the pharmaceutical industry.Huang underscored that the NMPA attaches great importance to the R&D of innovative drugs and external cooperation. The drug regulatory units will further optimize the review and approval process; support the introduction of original research drugs for domestic production; and enhance the confidence of multinational companies in investing and developing in China. Related NewsM Stanley: If CN-US Tariff War Diminishes Sharply, CN Dotcom/ Consumer Goods/ Healthcare Sectors Expected to Boom, but ST Patience/ Balanced Strategy AdvisedAt the same time, they will continue to improve relevant policies to support and guide enterprises and R&D institutes to increase R&D of innovative drugs and high-quality generic drugs, and actively participate in competition at home and abroad.